Logo image
26-A-19496-ACC CLINICAL OUTCOMES AMONG HFPEF PATIENTS ON SPIRONOLACTONE VS EPLERENONE: A REAL WORLD PROPENSITY MATCHED ANALYSIS
Abstract   Peer reviewed

26-A-19496-ACC CLINICAL OUTCOMES AMONG HFPEF PATIENTS ON SPIRONOLACTONE VS EPLERENONE: A REAL WORLD PROPENSITY MATCHED ANALYSIS

God-dowell O. Odukudu, Divine Dele, Ademola Ajibade, Francois Barrett, Chinelo Madekwe, Henry Ariri, Abdulkareem Murtala, Ephesians Nkwetta Anutebeh, Ogheneakpobor Ubogun, Omowunmi Fakorede, …
Journal of the American College of Cardiology, Vol.87(13 Supplement), p.A635
04/2026
DOI: 10.1016/j.jacc.2026.02.1675

View Online

Abstract

Background Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of heart failure cases and is challenging to treat, with few effective therapies. Mineralocorticoid receptor antagonists (MRAs) are commonly used, but data comparing eplerenone and spironolactone in HFpEF are limited. This study evaluates the clinical outcomes of eplerenone versus spironolactone in HFpEF patients using real-world data. Methods This retrospective cohort study utilized the TriNetX Research Network to compare outcomes in patients with HFpEF treated with eplerenone (n = 6,406) versus spironolactone (n = 385,794). Propensity score matching for demographics, comorbidities, and medications was done. The index event was the first documentation of diastolic heart failure with MRA initiation. Primary outcomes were all-cause mortality and hospitalization; secondary outcomes included progression to HFrEF, stroke, myocardial infarction, and acute heart failure exacerbation. Results After matching, 6,397 patients per cohort were well-balanced. Over a mean follow-up of 2.2 years, eplerenone was associated with lower all-cause mortality (21.2% vs. 26.7%), hospitalization (38.5% vs. 44.9%), progression to HFrEF (3.0% vs. 4.3%), acute MI (13.1% vs. 14.9%), and heart failure exacerbation (34.6% vs. 41.8%) (all p<0.01). Stroke rates were similar. Conclusion Eplerenone was associated with superior outcomes versus spironolactone in HFpEF, warranting confirmation in prospective trials.

Details

Metrics

1 Record Views
Logo image